Diabetes mellitus. Medication update.
Slagle
Mark
M
D001549:Benzamides / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000520:alpha-Glucosidases / Q000627:therapeutic use*
D001549:Benzamides; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; C030516:meglitinide; D008687:Metformin; C089946:2,4-thiazolidinedione; D000520:alpha-Glucosidases